A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation.

Trial Profile

A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 May 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
    • 17 Jan 2012 New source identified and integrated (Memorial Sloan-Kettering Cancer Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top